NextCure, Inc. (NXTC)

In November 2025, NextCure announced the closing of a $21.5 million PIPE financing. In January 2026, the company provided updates on its ADC pipeline progress and reported a preliminary year-end 2025 cash position, extending its cash runway into the first half of 2027. In March 2026, NextCure provided a business update and reported full-year 2025 financial results, and an abstract for SIM0505 was accepted for the ASCO 2026 meeting. In April 2026, NextCure received Fast Track Designation from the FDA for SIM0505 for the treatment of platinum-resistant ovarian cancer. In May 2026, the company reported its first-quarter 2026 financial results, highlighting the FDA Fast Track designation for SIM0505 and the initiation of a dose optimization study for SIM0505 in gynecologic cancers; Phase 1 dose escalation data for SIM0505 is expected to be presented at ASCO 2026 on June 1, 2026, and trading of NXTC stock was temporarily halted due to volatility.

As a clinical-stage biopharmaceutical company, NextCure, Inc. does not have commercialized products with traditional consumer demand seasonality. Its demand is primarily driven by ongoing research and development, clinical trial progress, regulatory milestones, and financing activities, which are not typically subject to seasonal fluctuations.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines for cancer and other immune-related diseases. The company's pipeline focuses on targeted therapies, including antibody-drug conjugates (ADCs), for patients who do not respond to current treatments. Its major product candidates include SIM0505, an ADC targeting CDH6 currently in Phase 1 clinical testing with Fast Track Designation for platinum-resistant ovarian cancer; LNCB74, an ADC targeting B7-H4 in Phase 1 clinical development; NC410, a fusion protein of LAIR-2; NC525, a novel LAIR-1 antibody; NC181, a humanized antibody targeting ApoE4 for Alzheimer's disease; and NC605, an antibody targeting Siglec-15.

NextCure, Inc. is headquartered in Beltsville, Maryland, United States. Clinical trials for SIM0505 are being conducted in the U.S. and China, with plans to expand into Canada and Europe in the second half of 2026.

Within the past year, there is no specific information indicating major negative events that have significantly impacted NextCure, Inc.'s brand reputation. The company has been actively providing business updates and reporting progress on its clinical programs, including receiving Fast Track Designation for SIM0505, which generally contributes positively to a biopharmaceutical company's reputation. However, shareholders have experienced substantial dilution in the past year, with total shares outstanding growing by 54.3%, which can be a point of concern for investors.

NextCure, Inc. is owned by a mix of institutional, insider, and retail investors. Institutional shareholders hold approximately 53.30% of the company, while NextCure insiders hold about 402.97%. Major institutional owners include Affinity Asset Advisors, LLC, Ikarian Capital, LLC, Sofinnova Investments, Inc., Squadron Capital Management LLC, Silverarc Capital Management, LLC, Exome Asset Management LLC, Pfizer Inc., AWM Investment Company, Inc., Vanguard Group Inc., BlackRock, Inc., and Simcere Pharmaceutical Group Limited. Key individual insider owners include Chau Quang Khuong, Orbimed Advisors LLC, Sofinnova Venture Partners IX LP, Canaan X LP, Timothy M. Shannon, Stella Xu, and Simcere Zaiming Inc.